Precigen (PGEN) Non-Current Deffered Revenue (2012 - 2025)
Precigen (PGEN) reported Non-Current Deffered Revenue of $95000.0 for Q3 2025, down 95.32% year-over-year from $2.0 million in Q3 2024, and down 94.77% quarter-over-quarter from $1.8 million in Q2 2025.
Precigen (PGEN) Non-Current Deffered Revenue (2012 - 2025) Analysis & Trends
Precigen (PGEN) has 14 years of Non-Current Deffered Revenue data on file, last reported at $95000.0 in Q3 2025.
- Non-Current Deffered Revenue for Q3 2025 came in at $95000.0, down 95.32% year-over-year; the trailing twelve-month figure through Sep 2025 was $95000.0 (down 95.32% YoY), and the FY2024 annual result was $1.9 million, up 6.38% from the prior year.
- Non-Current Deffered Revenue slipped to $95000.0 in Q3 2025 per PGEN's latest filing, from $1.8 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $23.0 million in Q1 2021 and troughed at $95000.0 in Q3 2025.
- A 5-year average of $8.4 million and a median of $1.8 million in 2025 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deffered Revenue gained 11.77% in 2024, then slumped 95.32% in 2025.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $23.0 million in 2021, then tumbled by 92.1% to $1.8 million in 2022, then changed by 0.0% to $1.8 million in 2023, then grew by 6.38% to $1.9 million in 2024, then sank by 95.09% to $95000.0 in 2025.
- Business Quant data shows PGEN's Non-Current Deffered Revenue at $95000.0 in Q3 2025, $1.8 million in Q2 2025, and $1.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 95,000.00 |
| Jun 30, 2025 | 1.82 Mn |
| Mar 31, 2025 | 1.84 Mn |
| Dec 31, 2024 | 1.93 Mn |
| Sep 30, 2024 | 2.03 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | 1.89 Mn |
| Dec 31, 2023 | 1.82 Mn |
| Sep 30, 2023 | 1.82 Mn |
| Jun 30, 2023 | 1.82 Mn |
| Mar 31, 2023 | 1.82 Mn |
| Dec 31, 2022 | 1.82 Mn |
| Sep 30, 2022 | 1.82 Mn |
| Jun 30, 2022 | 23.02 Mn |
| Mar 31, 2022 | 23.02 Mn |
| Dec 31, 2021 | 23.02 Mn |
| Sep 30, 2021 | 23.02 Mn |
| Jun 30, 2021 | 23.02 Mn |
| Mar 31, 2021 | 23.02 Mn |
| Dec 31, 2020 | 23.02 Mn |